Raymond James Starts Immunovant (IMVT) at Outperform

Raymond James analyst Danielle Brill initiates coverage on Immunovant (NASDAQ: IMVT) with a Outperform rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $32.59 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• BofA Securities Assumes Altice-USA (ATUS) at Underperform
• UBS Starts Mobimo Holding AG (MOBN:SW) at Neutral